10-Q 1 cbt-20240630.htm 10-Q 10-Q
false0000016040--09-30Q3ten years2021 2022 20232018 2019 2020 2021 2022 20232006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023http://fasb.org/us-gaap/2024#AccountsPayableAndAccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#AccountsPayableAndAccruedLiabilitiesCurrent0000016040us-gaap:ForeignCountryMember2023-10-012024-06-300000016040us-gaap:EmployeeSeveranceMember2024-06-300000016040us-gaap:EMEAMembercbt:ReinforcementMaterialsMember2023-04-012023-06-300000016040us-gaap:RetainedEarningsMember2024-06-300000016040us-gaap:CustomerRelationshipsMember2023-09-300000016040us-gaap:ParentMember2022-10-012022-12-310000016040us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-10-012024-06-3000000160402023-01-012023-03-310000016040cbt:FixedRateDebtMember2023-09-300000016040us-gaap:RetainedEarningsMember2023-01-012023-03-310000016040us-gaap:NoncontrollingInterestMember2023-12-310000016040us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-01-012024-03-310000016040us-gaap:CorporateNonSegmentMember2023-04-012023-06-300000016040srt:AmericasMembercbt:PerformanceChemicalsMember2024-04-012024-06-300000016040us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-04-012023-06-300000016040us-gaap:OtherRestructuringMember2024-01-012024-03-310000016040us-gaap:DevelopedTechnologyRightsMember2024-06-300000016040us-gaap:EmployeeSeveranceMember2024-03-310000016040srt:AmericasMembercbt:ReinforcementMaterialsMember2023-10-012024-06-300000016040us-gaap:NoncontrollingInterestMember2024-06-300000016040us-gaap:ParentMember2023-09-300000016040us-gaap:TrademarksMember2024-06-300000016040us-gaap:OperatingSegmentsMember2023-10-012024-06-300000016040us-gaap:EMEAMembercbt:ReinforcementMaterialsMember2022-10-012023-06-300000016040us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-03-310000016040cbt:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossAndPriorServiceCostCreditMember2023-04-012023-06-300000016040us-gaap:InternalRevenueServiceIRSMember2023-10-012024-06-300000016040cbt:CommonStockNetOfTreasuryStockMember2022-09-300000016040us-gaap:EmployeeSeveranceMember2024-01-012024-03-310000016040cbt:AccumulatedNetInvestmentHedgesGainLossExcludedFromEffectivenessTestingAndAmortizedToInterestExpenseMember2023-10-012024-06-300000016040cbt:CostOfSalesSellingAndAdministrativeExpenseAndResearchAndTechnicalExpenseMember2022-10-012023-06-300000016040srt:AmericasMember2023-04-012023-06-300000016040us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-09-300000016040us-gaap:RetainedEarningsMember2022-10-012022-12-310000016040us-gaap:AdditionalPaidInCapitalMember2022-10-012022-12-310000016040us-gaap:AccumulatedTranslationAdjustmentMember2022-10-012022-12-310000016040us-gaap:ShippingAndHandlingMemberus-gaap:MaterialReconcilingItemsMember2023-04-012023-06-300000016040srt:AsiaPacificMembercbt:ReinforcementMaterialsMember2023-10-012024-06-300000016040us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300000016040us-gaap:ParentMember2024-04-012024-06-300000016040us-gaap:OperatingSegmentsMembercbt:ReinforcementMaterialsMember2023-04-012023-06-300000016040us-gaap:OperatingSegmentsMember2022-10-012023-06-300000016040us-gaap:AccumulatedTranslationAdjustmentMember2023-03-310000016040us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310000016040cbt:PerformanceChemicalsMember2023-09-300000016040us-gaap:OperatingSegmentsMember2023-04-012023-06-300000016040cbt:PerformanceChemicalsMembersrt:AsiaPacificMember2022-10-012023-06-300000016040us-gaap:OtherRestructuringMember2024-03-310000016040cbt:OtherProductsAndServicesMemberus-gaap:MaterialReconcilingItemsMember2023-04-012023-06-300000016040srt:AsiaPacificMember2024-04-012024-06-300000016040us-gaap:NoncontrollingInterestMember2023-06-300000016040us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000016040cbt:CommonStockNetOfTreasuryStockMember2023-12-310000016040us-gaap:StateAndLocalJurisdictionMember2023-10-012024-06-3000000160402023-09-300000016040us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300000016040us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-10-012022-12-310000016040us-gaap:RetainedEarningsMember2023-09-300000016040cbt:OtherProductsAndServicesMemberus-gaap:MaterialReconcilingItemsMember2023-10-012024-06-300000016040us-gaap:ParentMember2022-12-310000016040us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-06-300000016040us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-09-300000016040srt:AsiaPacificMember2022-10-012023-06-300000016040cbt:FixedRateDebtMember2024-06-300000016040us-gaap:EMEAMember2023-10-012024-06-3000000160402022-12-310000016040us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310000016040us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-04-012024-06-3000000160402023-06-300000016040cbt:PerformanceChemicalsMemberus-gaap:EMEAMember2023-10-012024-06-300000016040us-gaap:NoncontrollingInterestMember2023-03-310000016040us-gaap:FairValueInputsLevel2Member2023-09-300000016040us-gaap:AccumulatedTranslationAdjustmentMember2023-12-310000016040us-gaap:NoncontrollingInterestMember2024-01-012024-03-310000016040srt:AmericasMember2024-04-012024-06-300000016040srt:AsiaPacificMembercbt:ReinforcementMaterialsMember2022-10-012023-06-300000016040us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-06-300000016040cbt:BOPREALBondsMember2024-04-012024-06-300000016040cbt:CommonStockNetOfTreasuryStockMember2023-10-012023-12-3100000160402024-04-012024-06-300000016040cbt:CommonStockNetOfTreasuryStockMember2022-10-012022-12-310000016040us-gaap:RetainedEarningsMember2023-10-012023-12-310000016040us-gaap:EMEAMember2023-04-012023-06-300000016040cbt:RespiratorLiabilitiesMember2023-09-300000016040cbt:OtherProductsAndServicesMemberus-gaap:MaterialReconcilingItemsMember2022-10-012023-06-300000016040us-gaap:RetainedEarningsMember2022-12-310000016040us-gaap:ParentMember2022-09-300000016040us-gaap:CostOfSalesMember2024-04-012024-06-3000000160402023-10-012024-06-300000016040us-gaap:OperatingSegmentsMembercbt:ReinforcementMaterialsMember2024-04-012024-06-300000016040us-gaap:NoncontrollingInterestMember2023-04-012023-06-300000016040us-gaap:ParentMember2023-01-012023-03-310000016040srt:WeightedAverageMember2024-06-300000016040srt:AmericasMember2022-10-012023-06-300000016040cbt:RevaluationOfNonFunctionalCurrencyMemberus-gaap:OtherNonoperatingIncomeExpenseMember2024-04-012024-06-300000016040us-gaap:OtherNonoperatingIncomeExpenseMember2023-10-012024-06-300000016040srt:MinimumMember2024-06-300000016040us-gaap:NoncontrollingInterestMember2022-09-3000000160402022-09-300000016040srt:AmericasMembercbt:ReinforcementMaterialsMember2024-04-012024-06-300000016040cbt:ReinforcementMaterialsMember2023-09-300000016040cbt:CommonStockNetOfTreasuryStockMember2023-09-300000016040cbt:RevaluationOfNonFunctionalCurrencyMemberus-gaap:OtherNonoperatingIncomeExpenseMember2023-10-012024-06-300000016040us-gaap:RetainedEarningsMember2024-03-310000016040us-gaap:AdditionalPaidInCapitalMember2023-10-012023-12-310000016040us-gaap:EmployeeSeveranceMember2023-09-300000016040us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-04-012023-06-300000016040us-gaap:EMEAMembercbt:ReinforcementMaterialsMember2024-04-012024-06-300000016040us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-01-012023-03-310000016040us-gaap:RetainedEarningsMember2023-12-310000016040us-gaap:ParentMember2024-01-012024-03-310000016040us-gaap:EmployeeSeveranceMember2024-04-012024-06-300000016040us-gaap:RetainedEarningsMember2023-03-310000016040us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300000016040srt:AmericasMembercbt:PerformanceChemicalsMember2023-04-012023-06-300000016040us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310000016040us-gaap:ParentMember2024-03-310000016040us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-03-310000016040us-gaap:OperatingSegmentsMember2024-04-012024-06-300000016040cbt:PrepaidExpensesAndOtherCurrentAssetsAccountsPayableAndAccruedLiabilitiesAndOtherAssetsMemberus-gaap:ForeignExchangeContractMember2023-09-300000016040us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300000016040us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-10-012023-12-3100000160402023-03-310000016040us-gaap:OperatingSegmentsMembercbt:ReinforcementMaterialsMember2023-10-012024-06-300000016040cbt:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossAndPriorServiceCostCreditMember2022-10-012023-06-3000000160402022-10-012023-06-300000016040srt:AsiaPacificMembercbt:ReinforcementMaterialsMember2023-04-012023-06-300000016040us-gaap:RetainedEarningsMember2024-01-012024-03-310000016040us-gaap:ParentMember2023-12-310000016040cbt:AccumulatedNetInvestmentHedgesGainLossExcludedFromEffectivenessTestingAndAmortizedToInterestExpenseMember2024-04-012024-06-300000016040srt:AmericasMembercbt:PerformanceChemicalsMember2022-10-012023-06-300000016040cbt:CostOfSalesSellingAndAdministrativeExpenseAndResearchAndTechnicalExpenseMember2024-04-012024-06-300000016040us-gaap:ParentMember2024-06-300000016040cbt:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossAndPriorServiceCostCreditMember2023-10-012024-06-300000016040us-gaap:AccumulatedTranslationAdjustmentMember2024-01-012024-03-310000016040us-gaap:SubsequentEventMembercbt:AssetPurchaseAgreementMember2024-07-192024-07-190000016040cbt:ReinforcementMaterialsMember2024-06-300000016040cbt:CommonStockNetOfTreasuryStockMember2023-06-300000016040srt:MaximumMember2024-06-300000016040us-gaap:CorporateNonSegmentMember2022-10-012023-06-300000016040us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300000016040srt:AsiaPacificMember2023-04-012023-06-300000016040cbt:PerformanceChemicalsMemberus-gaap:OperatingSegmentsMember2023-10-012024-06-300000016040srt:AsiaPacificMembercbt:ReinforcementMaterialsMember2024-04-012024-06-300000016040us-gaap:EMEAMember2024-04-012024-06-300000016040us-gaap:AccumulatedTranslationAdjustmentMember2023-06-300000016040us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-12-310000016040us-gaap:AccumulatedTranslationAdjustmentMember2024-03-310000016040cbt:BOPREALBondsMember2024-01-012024-03-310000016040us-gaap:AdditionalPaidInCapitalMember2022-09-3000000160402023-12-310000016040us-gaap:NoncontrollingInterestMember2023-10-012023-12-310000016040us-gaap:CostOfSalesMember2023-10-012024-06-300000016040us-gaap:EMEAMembercbt:ReinforcementMaterialsMember2023-10-012024-06-300000016040cbt:OtherProductsAndServicesMemberus-gaap:MaterialReconcilingItemsMember2024-04-012024-06-300000016040cbt:RMPlanAndPCPlanMember2024-04-012024-06-300000016040us-gaap:RetainedEarningsMember2023-06-300000016040us-gaap:OtherRestructuringMember2024-06-300000016040cbt:CommonStockNetOfTreasuryStockMember2024-03-310000016040us-gaap:EmployeeSeveranceMember2023-12-310000016040us-gaap:ParentMember2023-06-300000016040us-gaap:AccumulatedTranslationAdjustmentMember2023-10-012023-12-310000016040us-gaap:CorporateNonSegmentMember2023-10-012024-06-300000016040us-gaap:EmployeeSeveranceMember2023-10-012023-12-310000016040us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-03-310000016040us-gaap:CorporateNonSegmentMembercountry:AR2024-04-012024-06-300000016040us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-10-012023-06-3000000160402023-10-012023-12-310000016040us-gaap:MaterialReconcilingItemsMember2024-04-012024-06-300000016040us-gaap:ParentMember2023-03-310000016040cbt:CommonStockNetOfTreasuryStockMember2022-12-310000016040us-gaap:ParentMember2023-10-012023-12-3100000160402022-10-012022-12-3100000160402024-01-012024-03-310000016040us-gaap:CorporateNonSegmentMember2024-04-012024-06-300000016040us-gaap:OperatingSegmentsMembercbt:ReinforcementMaterialsMember2022-10-012023-06-3000000160402024-03-310000016040cbt:CommonStockNetOfTreasuryStockMember2024-04-012024-06-300000016040us-gaap:MaterialReconcilingItemsMember2022-10-012023-06-300000016040us-gaap:NoncontrollingInterestMember2023-01-012023-03-310000016040cbt:ReinforcementMaterialsMember2023-10-012024-06-300000016040us-gaap:CorporateNonSegmentMembercountry:AR2023-10-012024-06-300000016040us-gaap:ShippingAndHandlingMemberus-gaap:MaterialReconcilingItemsMember2022-10-012023-06-300000016040us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-04-012024-06-300000016040us-gaap:NoncontrollingInterestMember2024-03-310000016040us-gaap:AccumulatedTranslationAdjustmentMember2023-09-3000000160402024-08-010000016040us-gaap:ParentMember2023-04-012023-06-300000016040cbt:PerformanceChemicalsMemberus-gaap:OperatingSegmentsMember2024-04-012024-06-300000016040cbt:CommonStockNetOfTreasuryStockMember2023-03-310000016040srt:AsiaPacificMember2023-10-012024-06-300000016040us-gaap:CustomerRelationshipsMember2024-06-300000016040cbt:PerformanceChemicalsMemberus-gaap:OperatingSegmentsMember2022-10-012023-06-300000016040us-gaap:RetainedEarningsMember2023-04-012023-06-300000016040us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310000016040us-gaap:MaterialReconcilingItemsMember2023-04-012023-06-300000016040us-gaap:MaterialReconcilingItemsMember2023-10-012024-06-300000016040us-gaap:NoncontrollingInterestMember2022-10-012022-12-310000016040us-gaap:RetainedEarningsMember2024-04-012024-06-300000016040cbt:PrepaidExpensesAndOtherCurrentAssetsAccountsPayableAndAccruedLiabilitiesAndOtherAssetsMemberus-gaap:ForeignExchangeContractMember2024-06-300000016040us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-10-012024-06-3000000160402024-06-300000016040cbt:PerformanceChemicalsMemberus-gaap:EMEAMember2022-10-012023-06-300000016040us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300000016040srt:AmericasMembercbt:PerformanceChemicalsMember2023-10-012024-06-300000016040cbt:RespiratorLiabilitiesMember2024-06-300000016040cbt:RMPlanAndPCPlanMember2023-10-012024-06-300000016040cbt:CostOfSalesSellingAndAdministrativeExpenseAndResearchAndTechnicalExpenseMember2023-04-012023-06-300000016040us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300000016040us-gaap:TrademarksMember2023-09-300000016040us-gaap:NoncontrollingInterestMember2024-04-012024-06-300000016040cbt:PerformanceChemicalsMembersrt:AsiaPacificMember2023-04-012023-06-300000016040us-gaap:NoncontrollingInterestMember2022-12-310000016040cbt:AccumulatedNetInvestmentHedgesGainLossExcludedFromEffectivenessTestingAndAmortizedToInterestExpenseMember2022-10-012023-06-300000016040srt:AmericasMembercbt:ReinforcementMaterialsMember2023-04-012023-06-300000016040us-gaap:FairValueInputsLevel2Member2024-06-300000016040us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300000016040us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000016040cbt:AcceleratedDepreciationOnAssetsMember2023-10-012023-12-310000016040us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310000016040cbt:PerformanceChemicalsMemberus-gaap:EMEAMember2024-04-012024-06-300000016040cbt:CommonStockNetOfTreasuryStockMember2024-01-012024-03-310000016040cbt:AcceleratedDepreciationOnAssetsMember2023-09-300000016040us-gaap:AccumulatedTranslationAdjustmentMember2023-04-012023-06-300000016040cbt:PerformanceChemicalsMemberus-gaap:OperatingSegmentsMember2023-04-012023-06-300000016040cbt:CommonStockNetOfTreasuryStockMember2023-01-012023-03-310000016040cbt:PerformanceChemicalsMembersrt:AsiaPacificMember2023-10-012024-06-300000016040us-gaap:OtherRestructuringMember2024-04-012024-06-300000016040cbt:CostOfSalesSellingAndAdministrativeExpenseAndResearchAndTechnicalExpenseMember2023-10-012024-06-300000016040srt:AmericasMembercbt:ReinforcementMaterialsMember2022-10-012023-06-300000016040us-gaap:AccumulatedTranslationAdjustmentMember2022-09-300000016040srt:AmericasMember2023-10-012024-06-300000016040cbt:CommonStockNetOfTreasuryStockMember2024-06-300000016040us-gaap:OtherNonoperatingIncomeExpenseMember2024-04-012024-06-300000016040us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-12-310000016040us-gaap:ShippingAndHandlingMemberus-gaap:MaterialReconcilingItemsMember2023-10-012024-06-300000016040us-gaap:EMEAMember2022-10-012023-06-300000016040us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-3100000160402023-04-012023-06-300000016040us-gaap:NoncontrollingInterestMember2023-09-300000016040us-gaap:RetainedEarningsMember2022-09-300000016040cbt:SingleDevaluationActionMemberus-gaap:OtherNonoperatingIncomeExpenseMember2023-10-012023-12-310000016040us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310000016040us-gaap:DevelopedTechnologyRightsMember2023-09-300000016040us-gaap:AccumulatedTranslationAdjustmentMember2024-04-012024-06-300000016040us-gaap:AccumulatedTranslationAdjustmentMember2024-06-300000016040cbt:PerformanceChemicalsMember2024-06-300000016040cbt:PerformanceChemicalsMembersrt:AsiaPacificMember2024-04-012024-06-300000016040cbt:CommonStockNetOfTreasuryStockMember2023-04-012023-06-300000016040us-gaap:ShippingAndHandlingMemberus-gaap:MaterialReconcilingItemsMember2024-04-012024-06-300000016040cbt:PerformanceChemicalsMemberus-gaap:EMEAMember2023-04-012023-06-30xbrli:purexbrli:sharescbt:Segmentiso4217:USDiso4217:USDxbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2024

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 1-5667

 

Cabot Corporation

(Exact name of registrant as specified in its charter)

 

 

Delaware

04-2271897

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

 

Two Seaport Lane, Suite 1400

Boston, Massachusetts

02210-2019

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (617) 345-0100

 

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

Title of each class

Trading symbol(s)

Name of each exchange on which registered

Common Stock, $1 par value per share

CBT

The New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

Accelerated filer

 

 

 

 

Non-accelerated filer

Smaller reporting company

 

 

 

 

Emerging growth company

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

The Company had 54,823,821 shares of common stock, $1.00 par value per share, outstanding as of August 1, 2024.

 

 


 

INDEX

 

Part I.

Financial Information

 

 

 

 

 

 

Item 1.

Financial Statements (unaudited)

 

 

Consolidated Statements of Operations

3

 

Consolidated Statements of Comprehensive Income (Loss)

4

 

Consolidated Balance Sheets

5

 

Consolidated Statements of Cash Flows

7

 

 

Consolidated Statements of Changes in Stockholders’ Equity

8

 

Notes to the Consolidated Financial Statements

10

 

 

 

 

 

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

21

 

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

30

 

Item 4.

Controls and Procedures

30

 

 

 

Part II.

Other Information

 

 

 

 

 

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

31

 

Item 5.

Other Information

31

Item 6.

Exhibits

31

 

2


 

Part I. Financial Information

Item 1. Financial Statements

CABOT CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS

UNAUDITED

 

 

 

Three Months Ended June 30

 

 

Nine Months Ended June 30

 

 

 

2024

 

 

2023

 

 

2024

 

 

2023

 

 

 

(In millions, except per share amounts)

 

Net sales and other operating revenues

 

$

1,016

 

 

$

968

 

 

$

2,993

 

 

$

2,966

 

Cost of sales

 

 

760

 

 

 

745

 

 

 

2,273

 

 

 

2,352

 

Gross profit

 

 

256

 

 

 

223

 

 

 

720

 

 

 

614

 

Selling and administrative expenses

 

 

68

 

 

 

58

 

 

 

210

 

 

 

184

 

Research and technical expenses

 

 

16

 

 

 

15

 

 

 

46

 

 

 

43

 

Loss on sale of business

 

 

 

 

 

 

 

 

 

 

 

3

 

Income (loss) from operations

 

 

172

 

 

 

150

 

 

 

464

 

 

 

384

 

Interest and dividend income

 

 

8

 

 

 

7

 

 

 

25

 

 

 

22

 

Interest expense

 

 

(19

)

 

 

(24

)

 

 

(62

)

 

 

(69

)

Other income (expense)

 

 

(3

)

 

 

(3

)

 

 

(33

)

 

 

(13

)

Income (loss) from operations before income taxes
   and equity in earnings of affiliated companies

 

 

158

 

 

 

130

 

 

 

394

 

 

 

324

 

(Provision) benefit for income taxes

 

 

(40

)

 

 

(41

)

 

 

(121

)

 

 

(90

)

Equity in earnings of affiliated companies, net of tax

 

 

2

 

 

 

1

 

 

 

5

 

 

 

4

 

Net income (loss)

 

 

120

 

 

 

90

 

 

 

278

 

 

 

238

 

Net income (loss) attributable to noncontrolling interests, net
   of tax

 

 

11

 

 

 

8

 

 

 

35

 

 

 

27

 

Net income (loss) attributable to Cabot Corporation

 

$

109

 

 

$

82

 

 

$

243

 

 

$

211

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-average common shares outstanding:

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

55.1

 

 

 

56.1

 

 

 

55.3

 

 

 

56.2

 

Diluted

 

 

55.7

 

 

 

56.5

 

 

 

55.8

 

 

 

56.7

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnings (loss) per common share:

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

$

1.96

 

 

$

1.44

 

 

$

4.34

 

 

$

3.68

 

Diluted

 

$

1.94

 

 

$

1.43

 

 

$

4.30

 

 

$

3.65

 

 

The accompanying notes are an integral part of these consolidated financial statements.

3


 

CABOT CORPORATION

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

UNAUDITED

 

 

 

Three Months Ended June 30

 

 

Nine Months Ended June 30

 

 

 

2024

 

 

2023

 

 

2024

 

 

2023

 

 

 

(In millions)

 

Net income (loss)

 

$

120

 

 

$

90

 

 

$

278

 

 

$

238

 

Other comprehensive income (loss), net of tax

 

 

 

 

 

 

 

 

 

 

 

 

Foreign currency translation adjustment, net of tax

 

 

(66

)

 

 

(20

)

 

 

(19

)

 

 

117

 

Derivatives: net investment hedges

 

 

 

 

 

 

 

 

 

 

 

 

(Gains) losses reclassified to interest expense, net of tax

 

 

(1

)

 

 

(1

)

 

 

(3

)

 

 

(4

)

(Gains) losses excluded from effectiveness testing and amortized to interest expense, net of tax

 

 

1

 

 

 

 

 

 

2

 

 

 

1

 

Pension and other post-retirement benefit liability adjustments, net of tax

 

 

 

 

 

 

 

 

(1

)

 

 

(1

)

Other comprehensive income (loss), net of tax (provision) benefit of $ (1), $ —, $ 11 and $ —

 

 

(66

)

 

 

(21

)

 

 

(21

)

 

 

113

 

Comprehensive income (loss)

 

 

54

 

 

 

69

 

 

 

257

 

 

 

351

 

Net income (loss) attributable to noncontrolling interests, net
   of tax

 

 

11

 

 

 

8

 

 

 

35

 

 

 

27

 

Foreign currency translation adjustment attributable to
   noncontrolling interests, net of tax

 

 

(1

)

 

 

(6

)

 

 

(1

)

 

 

3

 

Comprehensive income (loss) attributable to noncontrolling interests

 

 

10

 

 

 

2

 

 

 

34

 

 

 

30

 

Comprehensive income (loss) attributable to Cabot Corporation

 

$

44

 

 

$

67

 

 

$

223

 

 

$

321

 

 

The accompanying notes are an integral part of these consolidated financial statements.

4


 

CABOT CORPORATION

CONSOLIDATED BALANCE SHEETS

ASSETS

UNAUDITED

 

 

 

June 30, 2024

 

 

September 30, 2023

 

 

 

(In millions)

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

197

 

 

$

238

 

Accounts and notes receivable, net of reserve for doubtful
   accounts of $
5 and $2

 

 

732

 

 

 

695

 

Inventories:

 

 

 

 

 

 

     Raw materials

 

 

145

 

 

 

148

 

     Finished goods

 

 

341

 

 

 

374

 

     Other

 

 

67

 

 

 

63

 

Total inventories

 

 

553

 

 

 

585

 

Prepaid expenses and other current assets

 

 

109

 

 

 

108

 

Total current assets

 

 

1,591

 

 

 

1,626

 

Property, plant and equipment

 

 

3,907

 

 

 

3,827

 

Accumulated depreciation

 

 

(2,477

)

 

 

(2,415

)

Net property, plant and equipment

 

 

1,430

 

 

 

1,412

 

Goodwill

 

 

132

 

 

 

134

 

Equity affiliates

 

 

24

 

 

 

20

 

Intangible assets, net

 

 

55

 

 

 

60

 

Deferred income taxes

 

 

166

 

 

 

180

 

Other assets

 

 

182

 

 

 

172

 

Total assets

 

$

3,580

 

 

$

3,604

 

 

The accompanying notes are an integral part of these consolidated financial statements.

5


 

CABOT CORPORATION

CONSOLIDATED BALANCE SHEETS

LIABILITIES AND STOCKHOLDERS’ EQUITY

UNAUDITED

 

 

 

June 30, 2024

 

 

September 30, 2023

 

 

 

(In millions, except share

 

 

 

and per share amounts)

 

Current liabilities:

 

 

 

 

 

 

Short-term borrowings

 

$

49

 

 

$

174

 

Accounts payable and accrued liabilities

 

 

626

 

 

 

600

 

Income taxes payable

 

 

34

 

 

 

40

 

Current portion of long-term debt

 

 

8

 

 

 

8

 

Total current liabilities

 

 

717

 

 

 

822

 

Long-term debt

 

 

1,083

 

 

 

1,094

 

Deferred income taxes

 

 

40

 

 

 

50

 

Other liabilities

 

 

244

 

 

 

231

 

Contingencies (Note E)

 

 

 

 

 

 

Stockholders' equity:

 

 

 

 

 

 

Preferred stock:

 

 

 

 

 

 

Authorized: 2,000,000 shares of $1 par value, Issued and Outstanding: None and none

 

 

 

 

 

 

Common stock:

 

 

 

 

 

 

Authorized: 200,000,000 shares of $1 par value, Issued: 54,949,872 and 55,379,636 shares, Outstanding: 54,816,803 and 55,243,804 shares

 

 

55

 

 

 

55

 

Less cost of 133,069 and 135,832 shares of common treasury stock

 

 

(3

)

 

 

(3

)

Additional paid-in capital

 

 

 

 

 

 

Retained earnings

 

 

1,676

 

 

 

1,574

 

Accumulated other comprehensive income (loss)

 

 

(382

)

 

 

(362

)

Total Cabot Corporation stockholders' equity

 

 

1,346

 

 

 

1,264

 

Noncontrolling interests

 

 

150

 

 

 

143

 

Total stockholders' equity

 

 

1,496

 

 

 

1,407

 

Total liabilities and stockholders' equity

 

$

3,580

 

 

$

3,604

 

 

The accompanying notes are an integral part of these consolidated financial statements.

6


 

CABOT CORPORATION

CONSOLIDATED STATEMENTS OF CASH FLOWS

UNAUDITED

 

 

 

Nine Months Ended June 30

 

 

 

2024

 

 

2023

 

 

 

(In millions)

 

Cash Flows from Operating Activities:

 

 

 

 

 

 

Net income (loss)

 

$

278

 

 

$

238

 

Adjustments to reconcile net income (loss) to cash provided by operating activities:

 

 

 

 

 

 

Depreciation and amortization

 

 

114

 

 

 

107

 

Loss on sale of business

 

 

 

 

 

3

 

Gain on sale of land

 

 

 

 

 

(1

)

Deferred tax provision (benefit)

 

 

7

 

 

 

(1

)

Equity in earnings of affiliated companies

 

 

(5

)

 

 

(4

)

Share-based compensation

 

 

19

 

 

 

15

 

Other non-cash (income) expense

 

 

60

 

 

 

2

 

Cash dividends received from equity affiliates

 

 

1

 

 

 

2

 

Changes in assets and liabilities:

 

 

 

 

 

 

Accounts and notes receivable

 

 

(47

)

 

 

173

 

Inventories

 

 

27

 

 

 

100

 

Prepaid expenses and other assets

 

 

(14

)

 

 

17

 

Accounts payable and accrued liabilities

 

 

38

 

 

 

(177

)

Income taxes payable

 

 

(6

)

 

 

(18

)

Other liabilities

 

 

16

 

 

 

1

 

Cash provided by (used in) operating activities

 

 

488

 

 

 

457

 

Cash Flows from Investing Activities:

 

 

 

 

 

 

Additions to property, plant and equipment

 

 

(149

)

 

 

(166

)

Proceeds from sale of land

 

 

 

 

 

7

 

Proceeds from sale of business

 

 

 

 

 

6

 

Proceeds from insurance settlements

 

 

 

 

 

12

 

Other

 

 

3

 

 

 

2

 

Cash provided by (used in) investing activities

 

 

(146

)

 

 

(139

)

Cash Flows from Financing Activities:

 

 

 

 

 

 

Proceeds from short-term borrowings

 

 

 

 

 

24

 

Repayments of short-term borrowings

 

 

(1

)

 

 

(48

)

Proceeds from issuance (repayments) of commercial paper, net

 

 

(123

)

 

 

(188

)

Proceeds from long-term debt, net of issuance costs

 

 

14

 

 

 

79

 

Repayments of long-term debt

 

 

(29

)

 

 

(88

)

Purchases of common stock

 

 

(106

)

 

 

(48

)

Proceeds from sales of common stock

 

 

15

 

 

 

4

 

Cash dividends paid to noncontrolling interests

 

 

(27

)

 

 

(41

)

Cash dividends paid to common stockholders

 

 

(69

)

 

 

(65

)

Cash provided by (used in) financing activities

 

 

(326

)

 

 

(371

)

Effects of exchange rate changes on cash

 

 

(57

)

 

 

67

 

Increase (decrease) in cash and cash equivalents

 

 

(41

)

 

 

14

 

Cash and cash equivalents at beginning of period

 

 

238

 

 

 

206

 

Cash and cash equivalents at end of period

 

$

197

 

 

$

220

 

 

The accompanying notes are an integral part of these consolidated financial statements.

7


 

CABOT CORPORATION

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

UNAUDITED

 

 

 

Common Stock, Net of Treasury Stock

 

 

Additional
Paid-in

 

 

Retained

 

 

Accumulated Other Comprehensive

 

 

Total Cabot Corporation Stockholders’

 

 

Noncontrolling

 

 

Total Stockholders’

 

 

 

Shares

 

 

Cost

 

 

Capital

 

 

Earnings

 

 

Income (Loss)

 

 

Equity

 

 

Interests

 

 

Equity

 

 

 

(In millions, except share amounts)

 

Balance at September 30, 2023

 

 

55,244

 

 

$

52

 

 

$

 

 

$

1,574

 

 

$

(362

)

 

$

1,264

 

 

$

143

 

 

$

1,407

 

Net income (loss)

 

 

 

 

 

 

 

 

 

 

 

50

 

 

 

 

 

 

50

 

 

 

11

 

 

 

61

 

Total other comprehensive income (loss)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

57

 

 

 

57

 

 

 

4

 

 

 

61

 

Cash dividends paid:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common stock, $0.40 per share

 

 

 

 

 

 

 

 

 

 

 

(22

)

 

 

 

 

 

(22

)

 

 

 

 

 

(22

)

Cash dividends declared to noncontrolling interests

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(12

)

 

 

(12

)

Issuance of stock under equity compensation plans

 

 

441

 

 

 

 

 

 

7

 

 

 

 

 

 

 

 

 

7

 

 

 

 

 

 

7

 

Share-based compensation

 

 

 

 

 

 

 

 

6

 

 

 

 

 

 

 

 

 

6

 

 

 

 

 

 

6

 

Purchase and retirement of common stock

 

 

(260

)

 

 

 

 

 

(13

)

 

 

(20

)

 

 

 

 

 

(33

)

 

 

 

 

 

(33

)

Balance at December 31, 2023

 

 

55,425

 

 

$

52

 

 

$

 

 

$

1,582

 

 

$

(305

)

 

$

1,329

 

 

$

146

 

 

$

1,475

 

Net income (loss)

 

 

 

 

 

 

 

 

 

 

 

84

 

 

 

 

 

 

84

 

 

 

13

 

 

 

97

 

Total other comprehensive income (loss)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(12

)

 

 

(12

)

 

 

(4

)

 

 

(16

)

Cash dividends paid:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common stock, $0.40 per share

 

 

 

 

 

 

 

 

 

 

 

(23

)

 

 

 

 

 

(23

)

 

 

 

 

 

(23

)

Cash dividends declared to noncontrolling interests

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(15

)

 

 

(15

)

Issuance of stock under equity compensation plans

 

 

122

 

 

 

 

 

 

6

 

 

 

 

 

 

 

 

 

6

 

 

 

 

 

 

6

 

Share-based compensation

 

 

 

 

 

 

 

 

7

 

 

 

 

 

 

 

 

 

7

 

 

 

 

 

 

7

 

Purchase and retirement of common stock

 

 

(289

)

 

 

 

 

 

(13

)

 

 

(11

)

 

 

 

 

 

(24

)

 

 

 

 

 

(24

)

Balance at March 31, 2024

 

 

55,258

 

 

$

52

 

 

$

 

 

$

1,632

 

 

$

(317

)

 

$

1,367

 

 

$

140

 

 

$

1,507

 

Net income (loss)

 

 

 

 

 

 

 

 

 

 

 

109

 

 

 

 

 

 

109

 

 

 

11

 

 

 

120

 

Total other comprehensive income (loss)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(65

)

 

 

(65

)

 

 

(1

)

 

 

(66

)

Cash dividends paid:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common stock, $0.43 per share

 

 

 

 

 

 

 

 

 

 

 

(24

)

 

 

 

 

 

(24

)

 

 

 

 

 

(24

)

Cash dividends declared to noncontrolling interests

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of stock under equity compensation plans

 

 

57

 

 

 

1

 

 

 

1

 

 

 

 

 

 

 

 

 

2

 

 

 

 

 

 

2

 

Share-based compensation

 

 

 

 

 

 

 

 

6

 

 

 

 

 

 

 

 

 

6

 

 

 

 

 

 

6

 

Purchase and retirement of common stock

 

 

(498

)

 

 

(1

)

 

 

(7

)

 

 

(41

)

 

 

 

 

 

(49

)

 

 

 

 

 

(49

)

Balance at June 30, 2024

 

 

54,817

 

 

$

52

 

 

$

 

 

$

1,676

 

 

$

(382

)

 

$

1,346

 

 

$

150

 

 

$

1,496

 

 

The accompanying notes are an integral part of these consolidated financial statements.

8


 

CABOT CORPORATION

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

UNAUDITED

 

 

 

Common Stock, Net of Treasury Stock

 

 

Additional
Paid-in

 

 

Retained

 

 

Accumulated Other Comprehensive

 

 

Total Cabot Corporation Stockholders’

 

 

Noncontrolling

 

 

Total Stockholders’

 

 

 

Shares

 

 

Cost

 

 

Capital

 

 

Earnings

 

 

Income (Loss)

 

 

Equity

 

 

Interests

 

 

Equity

 

 

 

(In millions, except share amounts)

 

Balance at September 30, 2022

 

 

56,249

 

 

$

52

 

 

$

1

 

 

$

1,284

 

 

$

(439

)

 

$

898

 

 

$

134

 

 

$

1,032

 

Net income (loss)

 

 

 

 

 

 

 

 

 

 

 

54

 

 

 

 

 

 

54

 

 

 

12

 

 

 

66

 

Total other comprehensive income (loss)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

81

 

 

 

81

 

 

 

6

 

 

 

87

 

Cash dividends paid: